Actinogen Financial Statements From 2010 to 2025
| ATGGF Stock | USD 0.04 0.00 0.00% |
Check Actinogen Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actinogen Medical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Actinogen financial statements analysis is a perfect complement when working with Actinogen Medical Valuation or Volatility modules.
Actinogen |
Actinogen Medical Limited Company Current Valuation Analysis
Actinogen Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Actinogen Medical Current Valuation | 125.91 M |
Most of Actinogen Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Actinogen Medical Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Actinogen Medical Limited has a Current Valuation of 125.91 M. This is 99.12% lower than that of the Healthcare sector and 97.29% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.24% higher than that of the company.
Actinogen Medical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Actinogen Medical's current stock value. Our valuation model uses many indicators to compare Actinogen Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Actinogen Medical competition to find correlations between indicators driving Actinogen Medical's intrinsic value. More Info.Actinogen Medical Limited is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Actinogen Medical's earnings, one of the primary drivers of an investment's value.About Actinogen Medical Financial Statements
Actinogen Medical stakeholders use historical fundamental indicators, such as Actinogen Medical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Actinogen Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Actinogen Medical's assets and liabilities are reflected in the revenues and expenses on Actinogen Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Actinogen Medical Limited. Please read more on our technical analysis and fundamental analysis pages.
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Actinogen Med operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Actinogen Pink Sheet
Actinogen Medical financial ratios help investors to determine whether Actinogen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Actinogen with respect to the benefits of owning Actinogen Medical security.